Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4

G. Nigro, A. Schiavetti, J. C. Booth, A. Clerico, C. Dominici, A. Krzysztofiak, M. Castello

Research output: Contribution to journalArticle

Abstract

Neuroblastoma is one of the most frequent solid tumors in childhood, rarely recurrent after five years from diagnosis. Cytomegalovirus (CMV), a major pathogen causing congenital birth defects and severe opportunistic diseases, has been shown to have teratogenic, immunodepressive and oncogenic properties. The case of a girl with stage 4S neuroblastoma diagnosed at three months and relapsed as stage 4 live years later is reported. In both circumstances, active CMV infection was revealed by positive CMV-specific IgM and IgA antibodies, CMV-DNAemia and CMV culture. At three months, the patient presented with subcutaneous nodules, hepatosplenomegaly and increased aminotransferase levels, and the opsoclonus-myoclonus syndrome. Mental retardation developed later on. At 5 years, relapsed neuroblastoma was preceded by a mononucleosis-like syndrome concomitant with active CMV infection and decreased levels of immune cells and natural killer activity. Clinical, virologic, and immunologic findings suggest an immune-mediated pathogenic role for CMV in this tumor.

Original languageEnglish
Pages (from-to)200-203
Number of pages4
JournalMedical and Pediatric Oncology
Volume24
Issue number3
DOIs
Publication statusPublished - 1995

Keywords

  • cell-mediated immunity
  • childhood
  • cytomegalovirus
  • Kinsbourne's syndrome
  • neuroblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4'. Together they form a unique fingerprint.

  • Cite this

    Nigro, G., Schiavetti, A., Booth, J. C., Clerico, A., Dominici, C., Krzysztofiak, A., & Castello, M. (1995). Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4. Medical and Pediatric Oncology, 24(3), 200-203. https://doi.org/10.1002/mpo.2950240311